Brief: Cantargia Presents Clinical Interim Results At ASCO 2022

Cantargia AB

27/05/2022 24:38

May 26 (Reuters) - Cantargia AB  CANTA.ST :
    * CANTARGIA PRESENTS CLINICAL INTERIM RESULTS AT ASCO 2022
HIGHLIGHTING THE POTENTIAL OF NADUNOLIMAB IN COMBINATION WITH
CHECKPOINT INHIBITOR

Source text for Eikon:  ID:nPre9nMbza 
Further company coverage:  CANTA.ST 

 ((Reuters.Briefs@thomsonreuters.com;))